Where are you?

To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.


Media and Investors Resources

Press Release, 1 February 2024

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

Press Release, 31 January 2024

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Press Release, 4 January 2024

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

Press Release, 27 December 2023

Adhoc Press Release

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

Press Release, 28 November 2023

Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

Press Release, 12 October 2023

Adhoc Press Release

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management